Entrada Therapeutics procures $116m Series B

Entrada Therapeutics Inc., a biotechnology company focused on treating devastating diseases using intracellular biologics, has secured $116 million in Series B financing.

Entrada Therapeutics Inc., a biotechnology company focused on treating devastating diseases using intracellular biologics, has secured $116 million in Series B financing. Wellington Management Company led the round.

Source: Press Release